Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028222 · ClinicalTrials.gov registry record · Phase 2
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT01028222 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT01028222, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
Interventions
- DRUG Nilotinib
- DRUG DTIC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028222
The ClinicalTrials.gov registry entry for NCT01028222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nilotinib is the first listed.
NCT01028222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028222 about?
NCT01028222 is a clinical study titled "A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation". The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
What is the current status of trial NCT01028222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2010-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01028222?
The interventions under investigation include: Nilotinib (DRUG), DTIC (DRUG).
Who is sponsoring clinical trial NCT01028222?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.